KalVista Pharmaceuticals
Update in progressKALV (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
KalVista Pharmaceuticals, Inc. is a biopharmaceutical company that develops oral therapies for rare diseases with unmet medical needs. Its lead candidate, EKTERLY, is a fast-acting, potent plasma kallikrein inhibitor for acute attacks of hereditary angioedema (HAE). The company is also advancing an orally disintegrating tablet program, KONFIDENT-KID for pediatric HAE, and KONFIDENT and KONFIDENT-S for adolescents and adults. HQ: Framingham, Massachusetts.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!